GeoVax Labs, Inc. (NASDAQ:GOVX) reported second-quarter 2026 financial results after the close on July 27, posting a net loss of $0.97 per share that came in well ahead of analyst expectations. The pre-revenue clinical-stage biotech, which focuses on vaccines and immunotherapies for infectious diseases and solid tumors, recorded no revenue during the quarter, matching the consensus estimate of zero. The smaller-than-expected loss was driven by aggressive cost-cutting as the company concentrates resources on its lead programs.
Earnings vs. Estimates
For the quarter ended June 30, 2026, GeoVax reported a GAAP net loss of $4.43 million, or $0.97 per share. Analysts had been modeling a loss of $2.94 per share, meaning the actual result was a roughly 67% smaller loss than anticipated. This is a meaningful beat on the bottom line, even though the company remains pre-revenue. Revenue came in at $0, in line with the consensus estimate, as the company’s previous government contract with BARDA for its COVID-19 vaccine program was terminated in April 2025.
The EPS beat reflects a sharp reduction in operating expenses. Research and development spending fell to $3.11 million from $4.73 million in the same quarter last year, while general and administrative costs dropped to $1.33 million from $1.54 million. Management attributed the declines to the discontinuation of the GEO-CM04S1 COVID-19 vaccine program and lower investor relations consulting costs.
Business Update
GeoVax used the earnings release to provide a progress report on its two main clinical-stage assets. The company said it continues to advance GEO-MVA, its MVA-based vaccine for mpox and smallpox, toward a planned pivotal immunobridging study in the fourth quarter. This program benefits from an expedited regulatory pathway established through Scientific Advice from the European Medicines Agency (EMA). Clinical-grade cGMP vaccine material has already been manufactured and released for the study.
On the oncology side, the company is progressing Gedeptin, a gene-directed enzyme prodrug therapy, toward combination strategies with immune checkpoint inhibitors. GeoVax highlighted its exclusive intellectual property license from Emory University covering Gedeptin in combination with PD-1 therapies. The drug has already completed a Phase 1/2 trial in advanced head and neck cancer.
The company also noted it has reprioritized its development portfolio, discontinuing work on its COVID-19 vaccine candidate GEO-CM04S1 to focus on programs with clearer regulatory pathways and more immediate commercial potential.
Financial Highlights
- Cash position: $3.1 million at June 30, 2026, unchanged from December 31, 2025.
- Net loss for the first half of 2026: $9.69 million, or $2.94 per share, compared to $10.73 million, or $19.72 per share, in the prior-year period.
- Total assets: $4.64 million, down from $6.34 million at year-end 2025.
- Common shares outstanding: 7.37 million at June 30, 2026, a significant increase from 1.73 million at year-end, reflecting equity raises during the period.
The company provided no forward-looking financial guidance in the release, which is typical for early-stage biotechs. Consensus analyst estimates for the full year 2026 project a loss of $17.80 per share on zero revenue. For Q3 2026, the street expects a loss of $3.35 per share.
Market Reaction
The stock has seen significant selling pressure in recent weeks, falling 22.8% over the past week, 31.5% over the past two weeks, and 42.4% over the past month. In after-hours trading following the earnings release, the stock was flat, suggesting that the substantial EPS beat is being tempered by the ongoing cash burn and the lack of a near-term revenue catalyst. The company’s $3.1 million cash balance may raise concerns about its ability to fund the planned GEO-MVA pivotal study without additional financing, though management noted disciplined capital deployment.
For a deeper look at GeoVax’s historical earnings performance, future projections, and analyst estimates, you can view the earnings page and the analyst ratings and forecast page.
This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
GeoVax Labs (GOVX): High Growth Stock Beats Earnings, Advances Mpox Vaccine and Cancer Therapy
GeoVax Labs, Inc. (NASDAQ:GOVX) reported second-quarter 2026 financial results after the close on July 27, posting a net loss of $0.97 per share that came in well ahead of analyst expectations. The pre-revenue clinical-stage biotech, which focuses on vaccines and immunotherapies for infectious diseases and solid tumors, recorded no revenue during the quarter, matching the consensus estimate of zero. The smaller-than-expected loss was driven by aggressive cost-cutting as the company concentrates resources on its lead programs.
Earnings vs. Estimates
For the quarter ended June 30, 2026, GeoVax reported a GAAP net loss of $4.43 million, or $0.97 per share. Analysts had been modeling a loss of $2.94 per share, meaning the actual result was a roughly 67% smaller loss than anticipated. This is a meaningful beat on the bottom line, even though the company remains pre-revenue. Revenue came in at $0, in line with the consensus estimate, as the company’s previous government contract with BARDA for its COVID-19 vaccine program was terminated in April 2025.
The EPS beat reflects a sharp reduction in operating expenses. Research and development spending fell to $3.11 million from $4.73 million in the same quarter last year, while general and administrative costs dropped to $1.33 million from $1.54 million. Management attributed the declines to the discontinuation of the GEO-CM04S1 COVID-19 vaccine program and lower investor relations consulting costs.
Business Update
GeoVax used the earnings release to provide a progress report on its two main clinical-stage assets. The company said it continues to advance GEO-MVA, its MVA-based vaccine for mpox and smallpox, toward a planned pivotal immunobridging study in the fourth quarter. This program benefits from an expedited regulatory pathway established through Scientific Advice from the European Medicines Agency (EMA). Clinical-grade cGMP vaccine material has already been manufactured and released for the study.
On the oncology side, the company is progressing Gedeptin, a gene-directed enzyme prodrug therapy, toward combination strategies with immune checkpoint inhibitors. GeoVax highlighted its exclusive intellectual property license from Emory University covering Gedeptin in combination with PD-1 therapies. The drug has already completed a Phase 1/2 trial in advanced head and neck cancer.
The company also noted it has reprioritized its development portfolio, discontinuing work on its COVID-19 vaccine candidate GEO-CM04S1 to focus on programs with clearer regulatory pathways and more immediate commercial potential.
Financial Highlights
The company provided no forward-looking financial guidance in the release, which is typical for early-stage biotechs. Consensus analyst estimates for the full year 2026 project a loss of $17.80 per share on zero revenue. For Q3 2026, the street expects a loss of $3.35 per share.
Market Reaction
The stock has seen significant selling pressure in recent weeks, falling 22.8% over the past week, 31.5% over the past two weeks, and 42.4% over the past month. In after-hours trading following the earnings release, the stock was flat, suggesting that the substantial EPS beat is being tempered by the ongoing cash burn and the lack of a near-term revenue catalyst. The company’s $3.1 million cash balance may raise concerns about its ability to fund the planned GEO-MVA pivotal study without additional financing, though management noted disciplined capital deployment.
For a deeper look at GeoVax’s historical earnings performance, future projections, and analyst estimates, you can view the earnings page and the analyst ratings and forecast page.
This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions.
Read full article here »